Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $308.5 million.

  • RxSight's Liabilities and Shareholders Equity fell 62.36% to $308.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2724.57%. This contributed to the annual value of $318.6 million for FY2024, which is 7450.73% up from last year.
  • RxSight's Liabilities and Shareholders Equity amounted to $308.5 million in Q3 2025, which was down 62.36% from $309.0 million recorded in Q2 2025.
  • RxSight's Liabilities and Shareholders Equity's 5-year high stood at $318.6 million during Q4 2024, with a 5-year trough of $94.9 million in Q2 2021.
  • For the 5-year period, RxSight's Liabilities and Shareholders Equity averaged around $219.5 million, with its median value being $194.0 million (2021).
  • As far as peak fluctuations go, RxSight's Liabilities and Shareholders Equity soared by 9142.51% in 2021, and later crashed by 2357.46% in 2022.
  • Quarter analysis of 5 years shows RxSight's Liabilities and Shareholders Equity stood at $192.7 million in 2021, then dropped by 22.08% to $150.2 million in 2022, then increased by 21.57% to $182.5 million in 2023, then soared by 74.51% to $318.6 million in 2024, then fell by 3.15% to $308.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $308.5 million in Q3 2025, compared to $309.0 million in Q2 2025 and $313.0 million in Q1 2025.